Navidea Biopharmaceuticals Inc.’s (NAVB) share price has entered into oversold territory with an RSI value of 23.98. The Zacks Consensus Estimate on Navidea Biopharmaceuticals Inc.’s earnings for the full year period has profit by 0.00 cents over the past two months to $-0.30 per share. Currently, Navidea Biopharmaceuticals Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (NAVB) after its recent drop.


NAVIDEA BIOPHARMACEUTICALS INC (NAVB): Free Stock Analysis Report


Zacks Investment Research